Table 1 Comparative table showing the structural differences between the three fusion proteins available for treatment of retinal diseases
From: Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
Aflibercept | Ziv-aflibercept | Conbercept | |
|---|---|---|---|
Structure | Fusion of the second domain of VEGFRs 1 and the third domain of VEGFR 2 to the Fc portion of human IgG1 | Fusion of the second domain of VEGFRs 1 and the third domain of VEGFR 2 to the Fc portion of human IgG1 | Fusion of the second domain of VEGFR1 and the third and fourth domains of VEGFR2 to the Fc portion of human IgG1 |
Mechanism of action | Binds to all isoforms of VEGF-A, VEGF-B and PIGF | Binds to all isoforms of VEGF-A, VEGF-B and PIGF | Binds with all isoforms of VEGF-A, VEGF-B, VEGF-C and PIGF |
Concentration | 40 mg/ml | 25 mg/ml | 10 mg/ml |
Binding affinity to VEGF-A (165) | Kd 0,49 Pm | Kd 0,49 Pm | Kd 0,5 Pm |
Molecular weight | 115 kDa | 115 kDa | 143 kDa |
Osmolarity | 286 mOsm | 1000 mOsm | Not published |
Half-life | 7, 1 days | 7, 1 days | 4, 2 days (rabbits) |